Across TCGA pan-cancer cohorts, TCEA3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TCEA3 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TCEA3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TCEA3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where TCEA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.544	0.739	.012	13	view →
PDAC	OS	Tertile	III,IV	0.739	0.166	.001	7	view →
LUAD	OS	Quartile	All	0.842	1.000	.017	5	view →
CCRCC	DFS	Median	All	0.632	0.847	.023	2	view →
LSCC	DFS	Tertile	All	0.970	0.874	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TCEA3 tumor-vs-normal RNA expression · all TCEA3 data types